Is serum GFAP IgM enough to diagnose autoimmune GFAP astrocytopathy?

Autoimmune GFAP astrocytopathy is an inflammatory central nervous system disorder whose established antibody association is GFAPα-specific IgG, especially in cerebrospinal fluid (CSF). This distinction is important when interpreting an isolated serum GFAP-IgM result.

Clinical and diagnostic evidence

• Serum GFAP-IgM alone does not establish autoimmune GFAP astrocytopathy. Its clinical significance is uncertain, and serum-only reactivity may represent nonspecific binding, assay-related reactivity, or peripheral immune activity rather than GFAP-directed CNS inflammation.
• Diagnosis requires a compatible subacute inflammatory CNS syndrome—such as meningoencephalitis, myelitis, optic neuritis, or combined encephalomyelitis—together with supportive investigations.
• MRI may show radial perivascular/periventricular enhancement, leptomeningeal enhancement, or longitudinal spinal-cord lesions, but these features are supportive rather than diagnostic in isolation. CSF inflammatory findings and exclusion of infectious, neoplastic, structural, and alternative autoimmune causes are also clinically important.

Antibody interpretation and biologic context

• CSF GFAPα-IgG is the diagnostically meaningful biomarker and is more informative than serum testing. Paired CSF and serum assessment, ideally incorporating tissue-based screening and GFAPα cell-based confirmation, provides a substantially more interpretable result than serum testing alone.
• Serum GFAP-IgM is not corroborated as a marker of astrocytic immune reactivity: measurable serum reactivity does not demonstrate intrathecal antibody production, astrocyte binding in disease-relevant tissue, or pathogenic astrocytic inflammation.
• Anti-GFAP IgM can occur following traumatic brain injury, reinforcing that this finding is not specific for autoimmune GFAP astrocytopathy.

Bottom line

• An isolated serum GFAP-IgM result should prompt confirmatory CSF-centered testing and clinicoradiologic assessment, not diagnose autoimmune GFAP astrocytopathy or independently justify immunotherapy.